[{"orgOrder":0,"company":"Arctic Vision","sponsor":"Clearside Biomedical","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Hormone","year":"2024","type":"Collaboration","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Arctic Vision","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arctic Vision \/ Clearside Biomedical","highestDevelopmentStatusID":"15","companyTruncated":"Arctic Vision \/ Clearside Biomedical"},{"orgOrder":0,"company":"Arctic Vision","sponsor":"Loyal Valley Capital","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Hormone","year":"2021","type":"Series B Financing","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Arctic Vision","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Arctic Vision \/ Loyal Valley Capital","highestDevelopmentStatusID":"10","companyTruncated":"Arctic Vision \/ Loyal Valley Capital"},{"orgOrder":0,"company":"Arctic Vision","sponsor":"Clearside Biomedical","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Hormone","year":"2021","type":"Licensing Agreement","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Arctic Vision","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Arctic Vision \/ Clearside Biomedical","highestDevelopmentStatusID":"10","companyTruncated":"Arctic Vision \/ Clearside Biomedical"},{"orgOrder":0,"company":"Arctic Vision","sponsor":"University of Hong Kong","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Oligonucleotide","year":"2021","type":"Collaboration","leadProduct":"ARVN601","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Arctic Vision","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arctic Vision \/ University of Hong Kong","highestDevelopmentStatusID":"4","companyTruncated":"Arctic Vision \/ University of Hong Kong"},{"orgOrder":0,"company":"Arctic Vision","sponsor":"Clearside Biomedical","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Arctic Vision","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Arctic Vision \/ Clearside Biomedical","highestDevelopmentStatusID":"15","companyTruncated":"Arctic Vision \/ Clearside Biomedical"},{"orgOrder":0,"company":"Arctic Vision","sponsor":"Clearside Biomedical","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Arctic Vision","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Arctic Vision \/ Clearside Biomedical","highestDevelopmentStatusID":"15","companyTruncated":"Arctic Vision \/ Clearside Biomedical"},{"orgOrder":0,"company":"Arctic Vision","sponsor":"Eyenovia","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pilocarpine Hydrochloride","moa":"M3 receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Arctic Vision","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Arctic Vision \/ Eyenovia","highestDevelopmentStatusID":"10","companyTruncated":"Arctic Vision \/ Eyenovia"},{"orgOrder":0,"company":"Arctic Vision","sponsor":"Eyenovia","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pilocarpine Hydrochloride","moa":"M3 receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Arctic Vision","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Arctic Vision \/ Eyenovia","highestDevelopmentStatusID":"10","companyTruncated":"Arctic Vision \/ Eyenovia"},{"orgOrder":0,"company":"Arctic Vision","sponsor":"Clearside Biomedical","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Arctic Vision","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Arctic Vision \/ Clearside Biomedical","highestDevelopmentStatusID":"15","companyTruncated":"Arctic Vision \/ Clearside Biomedical"}]

Find Clinical Drug Pipeline Developments & Deals by Arctic Vision

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : Arcatus is a proprietary suspension of the corticosteroid triamcinolone acetonide for administration to the suprachoroidal space for the treatment of macular edema associated with uveitis.

                          Product Name : Arcatus

                          Product Type : Hormone

                          Upfront Cash : Inapplicable

                          February 20, 2025

                          Lead Product(s) : Triamcinolone Acetonide

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Approved FDF

                          Sponsor : Clearside Biomedical

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details :

                          Product Name : Arcatus

                          Product Type : Hormone

                          Upfront Cash : Inapplicable

                          July 29, 2024

                          Lead Product(s) : Triamcinolone Acetonide

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Approved FDF

                          Sponsor : Clearside Biomedical

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details :

                          Product Name : Arcatus

                          Product Type : Hormone

                          Upfront Cash : Undisclosed

                          July 11, 2024

                          Lead Product(s) : Triamcinolone Acetonide

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Approved FDF

                          Sponsor : Clearside Biomedical

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          04

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details :

                          Product Name : Arcatus

                          Product Type : Hormone

                          Upfront Cash : Inapplicable

                          October 07, 2023

                          Lead Product(s) : Triamcinolone Acetonide

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Approved FDF

                          Sponsor : Clearside Biomedical

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details :

                          Product Name : MicroLine

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          June 07, 2022

                          Lead Product(s) : Pilocarpine Hydrochloride

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase III

                          Sponsor : Eyenovia

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details :

                          Product Name : Arcatus

                          Product Type : Hormone

                          Upfront Cash : Undisclosed

                          October 03, 2021

                          Lead Product(s) : Triamcinolone Acetonide

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase III

                          Sponsor : Loyal Valley Capital

                          Deal Size : $100.0 million

                          Deal Type : Series B Financing

                          blank

                          07

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details :

                          Product Name : Arcatus

                          Product Type : Hormone

                          Upfront Cash : Undisclosed

                          August 15, 2021

                          Lead Product(s) : Triamcinolone Acetonide

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase III

                          Sponsor : Clearside Biomedical

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          08

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details :

                          Product Name : ARVN601

                          Product Type : Oligonucleotide

                          Upfront Cash : Undisclosed

                          May 07, 2021

                          Lead Product(s) : ARVN601

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Preclinical

                          Sponsor : University of Hong Kong

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          09

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details :

                          Product Name : MicroLine

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 09, 2021

                          Lead Product(s) : Pilocarpine Hydrochloride

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase III

                          Sponsor : Eyenovia

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank